Table 2 Patient characteristics and available samples.
ID | sex | Age (years) | Previous therapy | Last therapy | Age (years) | Disease duration (years) | JCV-DNA copies/ml | EDSS | Available samples - time points | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
T0a | T1 | T2 | T3b | |||||||||||
at MS diagnosis | at the last therapy start | at PML onset | at the last therapy start | at PML onset | at PML onset | (months of therapy) | ||||||||
PML-NAT#1c | F | 21 | IFNβ 1a (30 µg/w; 22 and 44 µg 3 times/w) MTX (120 mg/m2) | NTZ | 39 | 41 | 19 | 20 | 24 | 7.5 | 0 | 6 | 12 | 34 |
PML-NAT#2 | F | 24 | IFNβ 1a (30 µg/w; 22 and 44 µg 3 times/w) | NTZ | 27 | 28 | 3 | 4 | 73 | 3.5 | 0 | 6 | — | 25 |
PML-NAT#3 | F | 35 | IFNβ 1a (22 and 44 µg 3 times/w) | NTZ | 47 | 48 | 12 | 14 | 13 | 3.5 | — | — | — | 16 |
PML-NAT#4 | F | 9 | IFNβ 1b | NTZ | 29 | 34 | 20 | 25 | 10 | 5 | — | — | — | 56 |
PML-ALEM#5 | F | 23 | IFNβ 1a (22 and 44 µg 3 times/w); fingolimod, GA, DMF | Alem | 30 | 31 | 8 | 9 | 197d | na | — | — | — | 15 |
MS#1 | M | 23 | IFNβ1a (22 µg 3 times/w) | NTZ | 37 | — | 17 | — | — | — | 0 | 6 | 12 | 15 |
MS#2 | F | 15 | IFNβ 1a (30 µg/w; 22 and 44 µg 3 times/w) | NTZ | 17 | — | 7 | — | — | — | 0 | 6 | 12 | 27 |
MS#3 | M | 31 | IFNβ 1a (30 µg/w and 22 µg 3 times/w); MTX (110 mg/m2) | NTZ | 37 | — | 12 | — | — | — | 0 | 6 | 12 | 23 |
MS#4 | F | 29 | IFNβ 1a (44 µg/3 times/w); IFNβ 1b; MTX (90 mg/m2); GA (20 mg/day) | NTZ | 41 | — | 15 | — | — | — | 0 | 6 | 12 | 32 |
MS#5 | F | 31 | IFNβ 1a (44 µg 3 times/w) | NTZ | 32 | — | 5 | — | — | — | 0 | 6 | 12 | 24 |
